Outcomes With Experimental Neoadjuvant T-VEC in Resectable Stage IIIB-IVM1a Melanoma

Data from the largest  randomized neoadjuvant trial in resectable stage IIIB–IVM1a melanoma to date were presented at ASCO 2019.

Source: CancerNetwork - June 7, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news